

Status (Multiple Items)

Drug Name	Tumour Group	Regimen Name on NCCP website	Regimen Number	
5-Fluorouracil	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378	
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377	
	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451	
		5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day	421	
		Aflibercept-14 days	238	
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy- Herskovic Regimen	460	
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585	
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328	
		FOLFIRI Therapy-14 day	227	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
		Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 500mg/m2) Therapy	427	
		5-Fluorouracil and Folinic Acid Therapy-14 day	660	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		Cetuximab and FOLFOX-4 Therapy	692	
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infu	739	
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusiona	816	
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusiona	832	
		Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450

5-Fluorouracil	Head & Neck	CARBOplatini (AUC 5) and 5-Fluorouracil 1000mg/m <sup>2</sup> /day Therapy – 28 day cycle	552	
		Cetuximab (weekly), CARBOPlatin AUC 5 and 5-FU 1000mg/m <sup>2</sup> /day Therapy - 21 day cycle	418	
		Cetuximab (weekly), CISPlatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle	417	
		CISPlatin and 5-Fluorouracil Therapy-28 day	314	
		DOCEtaxel, CISPlatin, 5-Fluorouracil and Radiotherapy	324	
		DOCEtaxel,CISPlatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		Neoadjuvant DOCEtaxel, CISPlatin, 5-Fluorouracil and Chemoradiation and Surgery	315	
		CARBOPlatin 70mg/m <sup>2</sup> and 5-Fluorouracil 600mg/m <sup>2</sup> with Radioth	589	
		CARBOPlatin AUC 4 and 5-Fluorouracil 600mg/m <sup>2</sup> with Radiothera	591	
		Pembrolizumab, CARBOPlatin (AUC 5) and 5-Fluorouracil Therapy	705	
		Pembrolizumab, CISPlatin and 5-Fluorouracil Therapy	706	
Abiraterone	Genitourinary	Abiraterone 1000mg and Prednisolone 5mg Therapy	577	
		Abiraterone and Prednisolone Therapy	103	
Acalabrutinib	Leukaemia	Acalabrutinib Capsules Monotherapy	656	
Afatinib	Lung	Afatinib Monotherapy	221	
Aflibercept	Gastrointestinal	Aflibercept-14 days	238	
Alectinib	Lung	Alectinib Monotherapy	401	
Alemtuzumab	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611	
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SI	638	
Anastrozole	Breast	Anastrozole Monotherapy	254	
Apalutamide	Genitourinary	Apalutamide therapy	574	
Arsenic trioxide	Leukaemia/BMT	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357	
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356	
Atezolizumab	Breast	Atezolizumab and nab-PACLitaxel Therapy	688	
		Genitourinary	Atezolizumab 1200mg Monotherapy	544
	Lung	Atezolizumab 1680mg Monotherapy – 28 Day	593	
		Atezolizumab Monotherapy-14 day	592	
		Atezolizumab 1200mg Monotherapy	544	
		Atezolizumab 1680mg Monotherapy – 28 Day	593	
		Atezolizumab Monotherapy-14 day	592	
Atezolizumab 1200mg, CARBOPlatin AUC 5 and Etoposide 100mg/m	689			
Avelumab	Skin/Melanoma	Avelumab Monotherapy	535	
Axicabtagene ciloleu	Lymphoma (CAR-T	Axicabtagene ciloleu (Yescarta®) (CAR-T) DLBCL and tMBCL	717	
Axitinib	Genitourinary	Axitinib Monotherapy	104	
		Pembrolizumab 200mg and Axitinib Therapy	583	
Azacitidine	Leukaemia/BMT	Azacitidine 100mg/m <sup>2</sup> 5-day Therapy	288	
		Azacitidine 75mg/m <sup>2</sup> 5-2-2 Therapy	287	
Bendamustine	Leukaemia/BMT	Bendamustine Monotherapy	527	
		Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529
		Obinutuzumab and Bendamustine Therapy-28 day cycle	424	
		riTUXimab and Bendamustine Therapy	345	
Bevacizumab	Breast	Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m <sup>2</sup> Therapy	738	
	Gastrointestinal	Bevacizamab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 10mg/kg-14days	212	

Bevacizumab	Gastrointestinal	Bevacizumab 15mg/kg - 21 days	215	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		Bevacizumab 7.5mg/kg-21days	214	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21	623	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21	623	
	Genitourinary	Bevacizumab 10mg/kg-14days	212	
	Gynaecology	Bevacizumab 10mg/kg-14days	212	
		Bevacizumab 15mg/kg - 21 days	215	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg	620	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg	766	
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22)The	769	
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771	
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin (CAELYX) 40mg,	772	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/	799	
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Be	811	
		Lung	Bevacizumab 15mg/kg - 21 days	215
			Bevacizumab 7.5mg/kg-21days	214
	Neuro-oncology	Lomustine and Bevacizumab 5mg/kg Therapy	742	
		Lomustine and Bevacizumab 7.5mg/kg Therapy	804	
		Bevacizumab 5mg/kg Monotherapy – 14 Day	813	
Bicalutamide	Genitourinary	Bicalutamide Therapy	482	
binimetinib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563	
Bleomycin	Lymphoma	ABVD Therapy	290	
		Escalated Dose BEACOPP 21 day Therapy	354	
	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
Blinatumomab	Leukaemia/BMT	Blinatumomab Therapy	538	
		Blinatumomab Therapy (ALL with MRD>0.1%)	590	
	Paediatric Oncology	Blinatumomab Paediatric Therapy	P00567	
		Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy	P00707	
Bortezomib	Myeloma	Bortezomib , Melphalan and Prednisolone	275	
		Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274	
		Bortezomib and Dexamethasone Therapy	270	
		Bortezomib Maintenance Therapy- 14 day	435	
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416	
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299	
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-I	273	
		Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601	
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28	643	
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone	703	
			752	
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone	755	
			756	
		Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Inductor	780	
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781	
		Bortezomib	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy
	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Ther	609		
	Daratumumab (SC 1800mg), Bortezomib (weekly) andDexamethasc	695		

Bosutinib	Leukaemia/BMT	Bosutinib Monotherapy	224	
Brentuximab vedotin	Leukaemia/BMT	Brentuximab vedotin Monotherapy	234	
		Brentuximab vedotin and Bendamustine Therapy	529	
	Lymphoma	Brentuximab vedotin and ESHAP therapy (BRESHAP)	530	
		Brentuximab vedotin Monotherapy	234	
		Brentuximab vedotin and ICE Therapy	528	
		Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and pre	801	
		Brentuximab vedotin Monotherapy	234	
Brigatinib	Lung	Brigatinib Therapy	562	
Busulfan	Transplant	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635	
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636	
		Busulfan/Cyclophosphamide MAC-MUD	639	
		Busulfan/Cyclophosphamide MAC-SIB	641	
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched S	662	
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched U	663	
Cabazitaxel	Genitourinary	Cabazitaxel and Prednisolone	101	
Cabozantinib	Genitourinary	Cabozantinib Therapy	518	
Capecitabine	Breast	Capecitabine Monotherapy	216	
		Lapatinib and Capecitabine	217	
	Gastrointestinal	Capecitabine 825mg/m2 and RT–7 day	586	
		Capecitabine and RT – 7 day	523	
		Capecitabine and Temozolomide Therapy*	505	
		Capecitabine Monotherapy	216	
		Capecitabine/Oxaliplatin (XELOX) Therapy	321	
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239	
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524	
		Gemcitabine + Capecitabine Therapy	384	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21	623	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		mitoMYcin and Capecitabine Chemoradiation Therapy	727	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21	623	
CARBOplatin	Breast	CARBOplatin (AUC4-6) Monotherapy-21 days	261	
		CARBOplatin (AUC4-6) Monotherapy-28 days	251	
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258	
		Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) The	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP	731	
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (T	775	
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(	789	
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin	790	
		Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422
			Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day		310
		TICE -Autologous Conditioning Germ Cell Tumour Regimen		437

CARBOplatin	Gynaecology	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419
		CARBOplatin (AUC 5-6) and Weekly PAclitaxel 80mg/m2 Therapy	308
		CARBOplatin (AUC4-6) Monotherapy-21 days	261
		CARBOplatin (AUC4-6) Monotherapy-28 days	251
		CARBOplatin (AUC5-7.5) and PAclitaxel 175mg/m2 Therapy	303
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab	499
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PAclitaxel 175mg	620
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2	624
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AU	676
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PAclitaxel 175mg/	716
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PAclitaxel 175mg	766
		Pembrolizumab, PAclitaxel 175mg/m2, CARBOplatin AUC 5 and Be	811
		Pembrolizumab, PAclitaxel 175mg/m2 and CARBOplatin AUC 5 The	817
		Head & Neck	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)
	CARBOplatin (AUC4-6) Monotherapy-21 days		261
	CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days		332
	CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle		552
	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle		418
	CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radioth		589
	CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiothera		591
	Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy		705
	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CARBOplatin (AUC6) and PAclitaxel 200mg/m2 Therapy	304
		CARBOplatin and Oral Etoposide Therapy-21 days	319
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Pembrolizumab, PAclitaxel and CARBOplatin (AUC 6) Therapy	579
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568
		PEMEtrexed and CARBOplatin Therapy	318
		Weekly CARBOplatin (AUC2) PAclitaxel 50mg/m2 Therapy	309
		CARBOplatin and vinORElbine Therapy-21 Day	614
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m	689
(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy		397	
Lymphoma	Brentuximab vedotin and ICE Therapy	528	
	ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842	
Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Th	751	
Carfilzomib	Myeloma	Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (20/70mg/m2 Once weekly) Dexamethasone (Kd) ther	595
carfilzomib	Myeloma	Carfilzomib and Dexamethasone (Kd) Therapy - 28 day	566
		Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexameth	405
Carmustine	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SI	638
Carmustine (BCNU)	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
Cemiplimab	Gynaecology	Cemiplimab Therapy	812
	Skin/Melanoma	Cemiplimab Therapy	812

Ceritinib	Lung	Ceritinib Monotherapy	340	
Cetuximab	Gastrointestinal	Cetuximab (14 days) and Irinotecan (14 days) Therapy	331	
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330	
		Cetuximab Monotherapy-7 days	207	
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585	
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328	
		Cetuximab and FOLFOX-4 Therapy	692	
		Cetuximab Therapy-14 days	732	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
	Head & Neck	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m <sup>2</sup> /day Therapy - 21 day cycle	418	
		Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle	417	
Cetuximab Monotherapy-7 days		207		
Chlorambucil	Leukaemia/BMT	Chlorambucil10mg/m <sup>2</sup> Therapy	411	
		Obinutuzumab and Chlorambucil Therapy	286	
	Lymphoma	Chlorambucil10mg/m <sup>2</sup> Therapy	411	
CISplatin	Gastrointestinal	CISplatin 75mg/m <sup>2</sup> and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen	460	
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473	
		CISplatin and Teysuno-28 day cycle	235	
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) Therapy- 21 day	383	
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502	
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594	
		Pembrolizumab 200mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infu	739	
		Nivolumab 240mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusiona	816	
		Nivolumab 480mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusiona	832	
		Genitourinary	CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT)	385
			CISplatin, Methotrexate and Vinblastine Therapy	337
	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 28 day		282	
	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy		333	
	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days		338	
	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (35mg/m <sup>2</sup> ) Therapy- 21		622	
	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 21		628	
	Gynaecology	CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT)	385	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA)	264	
		CISplatin (50mg/m <sup>2</sup> ) Chemoradiation followed by CARBOplatin (AU	676	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m <sup>2</sup> and CISplatin 50mg/l	799	
		Head & Neck	Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle	417
			CISplatin (100mg/m <sup>2</sup> ) with Radiotherapy (RT)	387
	CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT)		385	
	CISplatin and 5-Fluorouracil Therapy-28 day		314	
	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy		324	



CISplatin	Head & Neck	DOCeTaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day	517	
		Neoadjuvant DOCeTaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315	
		Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615	
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706	
	Lung	CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day	279	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281	
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569	
		PEMEtrexed and CISplatin Therapy	317	
		Vinorelbine and CISplatin Therapy-21 days	339	
		Vinorelbine and CISplatin Therapy-28 days	343	
		Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
			DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420
	Neuro-oncology	CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806	
	Lymphoma	(R**)-DHAP Therapy	395	
		Brentuximab vedotin and ESHAP therapyi (BRESHAP)	530	
		(R*)- ESHAP Therapy	394	
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDI ESHAP Therapy	441	
Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300		
	Etoposide and CISplatin 20mg/m2 (EP) Therapy	301		
Cladribine	Leukaemia/BMT	Cladribine 0.14mg/kg Day 1 to 5 Therapy	402	
		Cladribine 0.14mg/kg Weekly Therapy	469	
	Leukaemia/BMT, I	Cladribine 5 day and riTUXimab Therapy	531	
		Cladribine Weekly and riTUXimab Therapy	534	
Cobimetinib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373	
Crizotinib	Lung	Crizotinib Monotherapy	243	
Cyclophosphamide	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378	
		DOCeTaxel /Cyclophosphamide (TC) Therapy-21 day	250	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485	

Cyclophosphamide	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day fo	745
	Gynaecology	EMA/CO Therapy	248
	Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615
	Leukaemia/BMT	Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241
	Sarcoma	Etoposide and ifosfamide - vinCRiStine, DOXOrubicin and cyclopho:	675
			747
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRiStine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRiStine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		Obinutuzumab and CHOP Therapy – 21 day	549
		obinutuzumab and CVP therapy -21 days	550
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRiStine and prednisolONE (CI	841
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRiStine and f	667
		Dose Adjusted R (S/C)-EPOCH Therapy	672
		(*riTUXimab)-Gemcitabine Cyclophosphamide,vinCRiStine and Pred	737
		Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and pre	801
Myeloma		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299
	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-I	273	
Lymphoma and M	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438	
Lymphoma, Myelo	Cyclophosphamide 1500mg/m2 For Stem Cell Mobilisation	795	
Lymphoma (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecl	606	
	Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtag	608	
Leukaemia (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecl	607	
Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched	629	
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched	630	
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631	



Cyclophosphamide	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched S	662
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched U	663
Cyclophosphamide - Oral	Breast	Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
		Fludarabine, Cyclophosphamide and ritUXimab (FC Oral+R)	
	Leukaemia/BMT	Therapy	410
	Lymphoma	Dexamethasone, ritUXimab and Cyclophosphamide (DRC)Therapy	532
Cytarabine	Leukaemia/BMT	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		FLAG:Ida 8mg/m2 Therapy	362
		High Dose Cytarabine Therapy	365
		Intermediate Dose Cytarabine Therapy	364
		Gemtuzumab ozogamicin in combination with DAUNOrubicin and c	612
	Lymphoma	(R**)–DHAP Therapy	395
		BEAM Autologous Transplant Conditioning Protocol	408
		Brentuximab vedotin and ESHAP therapy (BRESHAP)	530
		High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRix) therapy	508
		LEAM Autologous Transplant Conditioning Protocol	468
		Nordic Therapy	393
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		ritUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper Cv	467
		(R*)- ESHAP Therapy	394
		High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day	666
		ESHAP Therapy	838
	Leukaemia	FLAG Therapy	363
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
Midostaurin and Intermediate Dose Cytarabine Consolidation Ther		683	
Transplant		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SI	638
Dabrafenib	Skin/Melanoma	Dabrafenib Monotherapy	237
		Trametinib and Dabrafenib Therapy	415
Dacarbazine	Sarcoma	Dacarbazine (1.2 g/m2) Therapy – 21 day	511
	Skin/Melanoma	Dacarbazine Therapy	464
	Lymphoma	ABVD Therapy	290
Dacomitinib	Lung	Dacomitinib Monotherapy	565
DACTINomycin	Gynaecology	DACTINomycin Therapy	247
		EMA/CO Therapy	248
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA)	264
Daratumumab	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560
Daratumumab	Myeloma	Daratumumab Monotherapy	426
Daratumumab SC	Myeloma	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Ther	609
		Daratumumab SC Monotherapy	604
		Daratumumab (SC 1800mg), Bortezomib (weekly) andDexamethasc	695
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone	755
			756
Daunorubicin	Leukaemia/BMT	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359

Daunorubicin	Leukaemia/BMT	Gemtuzumab ozogamicin in combination with DAUNOrubicin and c	612
	Leukaemia	Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
Decitabine	Leukaemia/BMT	Decitabine Monotherapy – AML (28 day cycle)	231
Degarelix	Genitourinary	Degarelix Therapy- 28 day	481
Denosumab	Breast, Genitourin	Denosumab 120mg Therapy	741
Dinutuximab beta	Paediatric		
	Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
DOCEtaxel	Breast	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250
		DOCEtaxel Monotherapy 100mg/m <sup>2</sup> – 21 day cycle	202
		DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
		DOXOrubicin 50mg/m <sup>2</sup> /DOCEtaxel 75mg/m <sup>2</sup> (AT 50/75) Therapy - 21 day cycle	423
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) The	722
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP	731
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(	789
		Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - :	796
		Gastrointestinal	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle
	FLOT Therapy-14 day		344
	Genitourinary	DOCEtaxel 75mg/m <sup>2</sup> - Prednisolone combination therapy	546
		DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
		DOCEtaxel Monotherapy 50mg/m <sup>2</sup> Monotherapy-14 day	313
	Gynaecology	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
	Head & Neck	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324
		DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323
		Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	315
	Lung	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
		Nindetanib Therapy	372
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501
DOXOrubicin	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin 50mg/m <sup>2</sup> /DOCEtaxel 75mg/m <sup>2</sup> (AT 50/75) Therapy - 21 day cycle	423
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432

DOXOrubicin	Breast	Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day fo	745	
	Gastrointestinal	DOXOrubicin (60mg/m2) Therapy	386	
	Genitourinary	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333	
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338	
		Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615	
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463	
		DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420	
		DOXOrubicin (60) and Ifosfamide Therapy	391	
		DOXOrubicin (75) and Ifosfamide Therapy	392	
		DOXOrubicin 75mg/m2 Monotherapy	500	
		Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclopho:	675	
			747	
		Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISline and Prednisolone (*R)-CHOP Therapy– 14 days	409
			(R*)-CHOP – 21 days	307
			(R**)- miniCHOP Therapy – 21 days	436
	ABVD Therapy		290	
	CHOEP Therapy– 21 days		396	
	Dose Adjusted R-EPOCH Therapy		355	
	Escalated Dose BEACOPP 21 day Therapy		354	
	Nordic Therapy		393	
	Obinutuzumab and CHOP Therapy – 21 day		549	
	R-CODOX-M Therapy (Patients greater than 65 years)		403	
	R-CODOX-M Therapy (Patients less than or equal to 65 years)		398	
	riTUXimab-HyperCVAD Therapy (MCL) – Part A		466	
	Cyclophosphamide, DOXOrubicin, vinCRISline and prednisoLONE (CI		841	
	riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISline and I		667	
	Dose Adjusted R (S/C)-EPOCH Therapy	672		
Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and pre	801			
Durvalumab	Lung	Durvalumab 10mg/kg Monotherapy-14 Day	576	
		Durvalumab 1500mg Monotherapy-28 Day	655	
Encorafenib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563	
Entrectinib	Lung	Entrectinib Therapy	702	
Enzalutamide	Genitourinary	Enzalutamide Monotherapy	233	
epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263	
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262	
	Gastrointestinal	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
	epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239		
Eribulin	Breast	EriBULLin Monotherapy	228	
		eriBULLin Monotherapy – 28 Day	743	
Erlotinib	Lung	Erlotinib Monotherapy	219	
Etoposide	Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453	
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437	

Etoposide	Gynaecology	EMA/CO Therapy	248	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA)	264	
	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561	
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271	
		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) -21 day	279	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m	689	
		Sarcoma	Ifosfamide Etoposide (IE) Therapy	596
			Etoposide and ifosfamide - vinCRISatine, DOXOrubicin and cyclophosphamide	747
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	
		BEAM Autologous Transplant Conditioning Protocol	408	
		Brentuximab vedotin and ESHAP therapy (BRESHAP)	530	
		CHOEP Therapy– 21 days	396	
		Dose Adjusted R-EPOCH Therapy	355	
		Escalated Dose BEACOPP 21 day Therapy	354	
		LEAM Autologous Transplant Conditioning Protocol	468	
		R-CEOP Therapy – 21 days	510	
		R-IVAC Therapy (Patients greater than 65 years)	404	
		R-IVAC Therapy (Patients less than or equal to 65 years)	399	
		SMILE Therapy (NK or T-cell lymphoma)	407	
		(R*)- ESHAP Therapy	394	
		Brentuximab vedotin and ICE Therapy	528	
		Dose Adjusted R (S/C)-EPOCH Therapy	672	
		ESHAP Therapy	838	
	ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842		
	Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy	751	
	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301	
	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SI	638	
	Etoposide Oral	Lung	CARBOplatin and Oral Etoposide Therapy-21 days	319
		Oral Etoposide Therapy	388	
Lymphoma	R-CEOP Therapy – 21 days	510		
Everolimus	Breast	Everolimus and Exemestane Therapy	322	
	Genitourinary	Everolimus Monotherapy	320	
	Neuroendocrine	Everolimus Monotherapy	320	
Exemestane	Breast	Everolimus and Exemestane Therapy	322	
		Exemestane Monotherapy	376	
Fedratinib	Leukaemia	Fedratinib Therapy	788	
Fludarabine	Leukaemia/BMT	FLAG:Ida 8mg/m2 Therapy	362	
		Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241	
	Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410		
	Leukaemia	FLAG Therapy	363	
Lymphoma (CAR-T)	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecle	606		

Fludarabine	Lymphoma (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtag	608	
	Leukaemia (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecl	607	
	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611	
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635	
	Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636		
Folinic Acid	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585	
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328	
		FOLFIRI Therapy-14 day	227	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50	427	
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428	
		Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50	427	
		5-Fluorouracil and Folinic Acid Therapy-14 day	660	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		Cetuximab and FOLFOX-4 Therapy	692	
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Lymphoma	R-CODOX-M Therapy (Patients greater than 65 years)	403
			R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
			SMILE Therapy (NK or T-cell lymphoma)	407
	riTUXimab, Methotrexate, Procarbazine and vinCRistine (R-MPV) –		664	
	Fulvestrant	Breast	Fulvestrant Therapy	361
	Gefitinib	Lung	Gefitinib Monotherapy	220
Gemcitabine	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524	
	Gastrointestinal	Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day	383	
		Gemcitabine (1000mg/m2) and RT therapy	521	
		Gemcitabine (1000mg/m2) Monotherapy - 28 day	284	
		Gemcitabine (1000mg/m2) Monotherapy - 56 day	283	
		Gemcitabine (400mg/m2) and RT therapy	522	
		Gemcitabine (600mg/m2) and RT therapy	559	
		Gemcitabine + Capecitabine Therapy	384	
		Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day	256	
		Genitourinary	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
			Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day	282
			Gemcitabine (1000mg/m2 ) and CISplatin (35mg/m2 ) Therapy- 21	622

Gemcitabine	Genitourinary	Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 21	628
	Gynaecology	Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 4) Therapy- 21 day	306
		Gemcitabine (1000mg/m <sup>2</sup> ), CARBOplatin (AUC 4) and Bevacizumab	499
	Head & Neck	Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (80mg/m <sup>2</sup> ) Therapy - 21 day	517
		Gemcitabine (1250mg/m <sup>2</sup> ) Monotherapy - 21 day	514
	Lung	Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 5) Therapy- 21 day	310
		Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day	284
		Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (75mg/m <sup>2</sup> ) Therapy- 21 day	281
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501
	Lymphoma	R-Gemcitabine (1000mg/m <sup>2</sup> ) Oxaliplatin Therapyi - 14 day	506
riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDI		441	
(*riTUXimab)-Gemcitabine CyclophosphamideinCRISStine and Pred		737	
Gemtuzumab ozoga	Leukaemia/BMT	Gemtuzumab ozogamicin in combination with DAUNOrubicin and c	612
Goserelin	Genitourinary	Goserelin 10.8mg-12 Weekly Therapy	477
		Goserelin 3.6mg Therapy- 4 weeks	478
Ibrutinib	Lymphoma	Ibrutinib Therapy (Mantly Cell Lymphoma)	297
	Leukaemia	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)	296
Idarubicin	Leukaemia/BMT	FLAG:Ida 8mg/m <sup>2</sup> Therapy	362
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
Idelalisib	Leukaemia/BMT	Idelalisib and riTUXimab Therapy	389
	Lymphoma	Idelalisib Monotherapy	291
Ifosfamide	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy
		DOXOrubicin (75) and Ifosfamide Therapy	392
		Ifosfamide Etoposide (IE) Therapy	596
		Etoposide and ifosfamide - vinCRISStine, DOXOrubicin and cyclopho:	675
			747
		Infusional Ifosfamide Therapy	679
	Lymphoma	(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
SMILE Therapy (NK or T-cell lymphoma)		407	
Brentuximab vedotin and ICE Therapy		528	
	ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842	
Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Th	751	
Imatinib	Sarcoma	Imatinib Therapy-GIST	335
Inotuzumab ozogamicin	Leukaemia/BMT	Inotuzumab ozogamicin Monotherapy	537
Ipilimumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Lung	Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792
	Skin/Melanoma	Ipilimumab Monotherapy	105
		Nivolumab 3mg Ipilimumab 1mg Therapy	551
	Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431	
Irinotecan	Gastrointestinal	Aflibercept-14 days	238
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585



Irinotecan	Gastrointestinal	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOXIRI Therapy	555
		Irinotecan Monotherapy - 21 days	213
		Modified FOLFIRINOX Therapy	515
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Irinotecan 150mg/m2 Monotherapy - 28 days	654
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
Isotretinoin	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
Ixazomib	Myeloma	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
Lapatinib	Breast	Lapatinib and Capecitabine	217
Larotrectinib	Tumour Agnostic	Larotrectinib Monotherapy - Adult	758
		Larotrectinib Monotherapy - Paediatric	P00760
L-Asparaginase	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
Lenalidomide	Myeloma	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
		Lenalidomide 25mg and Dexamethasone Therapy - 28 day	218
		Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643
		Bortezomib, Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781
Lenalidomide RVD lite Maintenance Therapy	782		
Lenvatinib	Gastrointestinal	Lenvatinib -HCC Therapy	644
Lenvatinib	Head & Neck	Lenvatinib -DTC Therapy	295
Letrozole	Breast	Letrozole Monotherapy	371
Leuprorelin	Genitourinary	Leuprorelin 3.75mg Therapy-28 day	494
		Leuprorelin 30mg Therapy- 24 weeks	493
		Leuprorelin 45mg Therapy- 24 week	491
		Leuprorelin 7.5mg Therapy- 28 day	490
		Leuprorelin 11.25mg Therapy- 12 weeks	492
Leuprorelin	Genitourinary	Leuprorelin 22.5mg Therapy- 12 weeks	479
Lomustine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658
		Lomustine and Bevacizumab 5mg/kg Therapy	742
		Lomustine and Bevacizumab 7.5mg/kg Therapy	804
		Lomustine 130mg/m2 Therapy	805
		CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806
	Lymphoma	LEAM Autologous Transplant Conditioning Protocol	468
Lorlatinib	Lung	Lorlatinib therapy	570
Melphalan	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
		LEAM Autologous Transplant Conditioning Protocol	468
	Myeloma	Bortezomib , Melphalan and Prednisolone	275
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625

Melphalan	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SI	638
MESNA	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
	Lymphoma and M	Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438
Methotrexate	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Gynaecology	EMA/CO Therapy	248
		Intrathecal Methotrexate for CNS Prophylaxis in GTN	249
		Methotrexate 8 day Charing Cross Regimen	246
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA) (MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	264
	Sarcoma	VinBLAStine and Methotrexate Therapy	463
		VinBLAStine and Methotrexate Therapy	554
	Lymphoma	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		SMILE Therapy (NK or T-cell lymphoma)	407
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper Cv	467
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) –	664
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) –	664
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched	629
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched	630
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
		Busulfan/Cyclophosphamide MAC-MUD	639
Busulfan/Cyclophosphamide MAC-SIB		641	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched S		662	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched U		663	
Methylprednisolone	Lymphoma	(R*)- ESHAP Therapy	394
		ESHAP Therapy	838
Midostaurin	Leukaemia	Midostaurin Maintenance Therapy	661
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
		Midostaurin and Intermediate Dose Cytarabine Consolidation Ther:	683
Mifamurtide	Sarcoma	Mifamurtide	100
mitoMYcin	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
		mitoMYcin and Capecitabine Chemoradiation Therapy	727
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
Mogamulizumab	Lymphoma	Mogamulizumab Therapy	761
Nab-PACLitaxel	Breast	Atezolizumab and nab-PACLitaxel Therapy	688
Nab-PACLitaxel (Abraxane®)	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	230

Nab-PACLitaxel	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	736
	Gastrointestinal	Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day	256
Nindetanib	Lung	Nindetanib Therapy	372
Niraparib	Gynaecology	Niraparib Monotherapy	571
Nivolumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusiona	816
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusiona	832
	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Head & Neck	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Lung	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792
	Skin/Melanoma	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431
Lymphoma	Nivolumab Monotherapy 240mg-14 day	483	
	Nivolumab Monotherapy 480mg-28day	484	
Obinutuzumab	Leukaemia/BMT	Obinutuzumab and Chlorambucil Therapy	286
		Lymphoma	Obinutuzumab and Bendamustine Therapy-28 day cycle
	Lymphoma	Obinutuzumab and CHOP Therapy – 21 day	549
		obinutuzumab and CVP therapy -21 days	550
Olaparib	Genitourinary	Olaparib (Tablet) Monotherapy	588
	Gynaecology	Olaparib (Tablet) Monotherapy	588
Osimertinib	Lung	Osimertinib Monotherapy	353
Oxaliplatin	Gastrointestinal	Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
		Capecitabine/Oxaliplatin (XELOX) Therapy	321
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239
		FLOT Therapy-14 day	344
		FLOX Therapy	486
		FOLFIRINOX Therapy	329
		FOLFOX-4 Therapy-14 day	210
		FOLFOXIRI Therapy	555
		Modified FOLFIRINOX Therapy	515
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509
		Modified FOLFOX-6 Therapy-14 day	209
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Cetuximab and FOLFOX-4 Therapy	692
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
		Cetuximab and FOLFOX-6 (modified) Therapy	733
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
		Lymphoma	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day
	PACLitaxel	Breast	CARBoplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)			278

PACLitaxel	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day fo	745
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (T	775
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin	790
		Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therap	797
		PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
	Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422
		PACLitaxel Monotherapy 80mg/m2 7day	226
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
	Gynaecology	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg	620
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AU	676
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/	716
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg	766
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22)The	769
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/i	799
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Be	811
Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 The		817	
Lung		CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579
	Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy	309	
	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226	
	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621	
Palbociclib	Breast	Palbociclib Therapy-28 day	414
Panitumumab	Gastrointestinal	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447

Panitumumab	Gastrointestinal	Panitumumab 6mg/kg Therapy	225	
Pazopanib	Genitourinary	Pazopanib Therapy	445	
	Sarcoma	Pazopanib Therapy	445	
Pegylated Liposomal DOXOrubicin (CAELYX)	Breast	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX) ® 28 days	205	
		Gynaecology	Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX) ® 28 days	205
			Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
			Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2	624
			Bevacizumab 10mg/kg and Pegylated DOXOrubicin (CAELYX) 40mg,	772
	Sarcoma	Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX) ® 21 days	462	
		Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX) ® 28 days	205	
	Pembrolizumab	Gastrointestinal	Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infu	739
Genitourinary		Pembrolizumab 200mg Monotherapy	455	
		Pembrolizumab 400mg Monotherapy	558	
		Pembrolizumab 200mg and Axitinib Therapy	583	
Gynaecology		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Be	811	
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Ther	817	
Head & Neck		Pembrolizumab 400mg Monotherapy	558	
		Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705	
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706	
Lung		Pembrolizumab 200mg Monotherapy	455	
		Pembrolizumab 400mg Monotherapy	558	
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579	
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568	
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569	
Skin/Melanoma		Pembrolizumab 200mg Monotherapy	455	
		Pembrolizumab 400mg Monotherapy	558	
Lymphoma		Pembrolizumab 200mg Monotherapy	455	
		Pembrolizumab 400mg Monotherapy	558	
Head and Neck	Pembrolizumab 200mg Monotherapy	455		
	Lung	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568	
Pembrolizumab, PEMEtrexed and CISplatin Therapy		569		
PEMEtrexed and CARBOplatin Therapy		318		
PEMEtrexed and CISplatin Therapy		317		
PEMEtrexed Monotherapy		222		
Pertuzumab	Breast	Pertuzumab + Trastuzumab + DOCEtaxel	204	
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350	
		Pertuzumab Trastuzumab and VinORELBine	526	
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507	
		Pertuzumab and Trastuzumab Therapy	726	
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) The	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP	731	
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (T	775	
Pertuzumab/Trastu	Breast	Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy	785	
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(	789	
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin	790	
		Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - :	796	
		Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therap	797	
		Pertuzumab Trastuzumab (Phesgo®) and vinORELBine	798	
Pixantrone	Lymphoma	Pixantrone Therapy	255	



Plerixafor	Lymphoma, Myelc	Plerixafor and G-CSF Therapy	536
Polatuzumab vedot	Lymphoma	Polatuzumab Vedotin, Bendamustine and ritUXimab Therapy	685
Pomalidomide	Myeloma	Pomalidomide and Dexamethasone	245
Pomalidomide	Myeloma	Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601
Ponatinib	Leukaemia/BMT	Ponatinib Therapy	302
Procarbazine	Neuro-oncology	Procarbazine Lomustine and VinCRISine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISine (PCV) Therapy – 56 days	658
	Lymphoma	Escalated Dose BEACOPP 21 day Therapy	354
		ritUXimab, Methotrexate, Procarbazine and vinCRISine (R-MPV) –	664
Radium 223	Genitourinary	Radium 223 Therapy	257
Regorafenib	Gastrointestinal	Regorafenib Monotherapy	244
Ribociclib	Breast	Ribociclib Therapy-28 day	525
ritUXimab	Leukaemia/BMT	Fludarabine, Cyclophosphamide and ritUXimab (FC IV+R) Therapy	241
		Fludarabine, Cyclophosphamide and ritUXimab (FC Oral+R) Therapy	410
		Idelalisib and ritUXimab Therapy	389
		Venetoclax and Rituximab therapy	575
	Lymphoma	(**ritUXimab) Cyclophosphamide, DOXOrubicin,vinCRISine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*ritUXimab), Cyclophosphamide VinCRISine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		(R**)-DHAP Therapy	395
		(R**)-ICE ((ritUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		Dexamethasone, ritUXimab and Cyclophosphamide (DRC)Therapy	532
		Dose Adjusted R-EPOCH Therapy	355
		High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRix) therapy	508
		Nordic Therapy	393
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506
		ritUXimab 375 mg/m2 Combination Therapy-21 day	542
		RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day	543
		RiTUXimab 375 mg/m2 Maintenance Therapy-84 day	540
		RiTUXimab 375 mg/m2 Therapy-7 day	541
		ritUXimab and Bendamustine Therapy	345
		ritUXimab-HyperCVAD Therapy (MCL) – Part A	466
	R-IVAC Therapy (Patients greater than 65 years)	404	
	R-IVAC Therapy (Patients less than or equal to 65 years)	399	
	ritUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper Cv	467	
	(R*)- ESHAP Therapy	394	
	ritUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDI	441	
	RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day	599	
	RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day	600	
	ritUXimab, Methotrexate, Procarbazine and vinCRISine (R-MPV) –	664	
ritUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISine and f	667		
Dose Adjusted R (S/C)-EPOCH Therapy	672		
Polatuzumab Vedotin, Bendamustine and ritUXimab Therapy	685		



riTUXimab	Lymphoma	(*riTUXimab)-Gemcitabine Cyclophosphamide in CRISTine and Pred	737
	Leukaemia/BMT, I	Cladribine 5 day and riTUXimab Therapy	531
		Cladribine Weekly and riTUXimab Therapy	534
	Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Th	751
Ruxolitinib	Leukaemia/BMT	Ruxolitinib Monotherapy	229
Siltuximab	Lymphoma	Siltuximab Monotherapy	277
Sorafenib	Gastrointestinal	Sorafenib Therapy	294
	Genitourinary	Sorafenib Therapy	294
	Head & Neck	Sorafenib Therapy	294
Sunitinib	Genitourinary	SUNitinib 50mg Therapy (21 days)	719
	Sarcoma	SUNitinib 50mg Therapy (21 days)	719
Sunitinib	Genitourinary	Sunitinib 50mg Therapy	325
	Sarcoma	Sunitinib 50mg Therapy	325
	Neuroendocrine	Sunitinib 37.5mg Therapy	327
Talazoparib	Breast	Talazoparib Therapy	605
Tamoxifen	Breast	Tamoxifen Monotherapy	253
Temozolomide	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505
	Neuro-oncology	Temozolomide Recurrent Therapy	342
		Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years	461
		Temozolomide with RT and Adjuvant Therapy	334
Temsirolimus	Genitourinary	Temsirolimus Monotherapy	326
Teysuno	Gastrointestinal	CISplatin and Teysuno-28 day cycle	235
Thalidomide	Myeloma	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone	755
			756
Thiotepa	Lymphoma	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
Tipiracil	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382
Tisagenlecleucel	Paediatric Oncology	Tisagenlecleucel	P00748
	Leukaemia (CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL	686
	Lymphoma (CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL	687
Tivozanib	Genitourinary	Tivozanib Therapy	564
Topotecan	Gynaecology	Topotecan Monotherapy-5 day	311
		Topotecan Monotherapy-Weekly	312
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771
	Lung	Topotecan Monotherapy-5 day	311
		Topotecan Oral Monotherapy	587
Trabectedin	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
	Sarcoma	Trabectedin Monotherapy	374
Trametinib	Skin/Melanoma	Trametinib and Dabrafenib Therapy	415
Trastuzumab	Breast	Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (T	775
	Gastrointestinal	Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
Trastuzumab	Breast	PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
Trastuzumab emtar	Breast	Trastuzumab Emtansine (Kadcyla®) Early Breast Cancer Therapy- 21	659
Trastuzumab Emtansine (Kadcyla®)	Breast	Trastuzumab Emtansine (Kadcyla®) - 21 days	206

Trastuzumab IV	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		Trastuzumab (IV) Monotherapy 21 days	200
		Trastuzumab (IV) Monotherapy 7 days	201
		Pertuzumab and Trastuzumab Therapy	726
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day fo	745
		Trastuzumab SC	Breast
Trastuzumab SC 21 days-Early Breast Cancer	285		
Trastuzumab	Breast	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	272
Trastuzumab IV	Breast	DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
Trastuzumab SC	Breast	DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) The	722
Tretinoin (ATRA)	Leukaemia/BMT	DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHF)	731
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356
Trifluridine	Gastrointestinal	Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366
		Trifluridine and Tipiracil (Lonsurf®) Therapy	382
		Triptorelin 11.25mg Therapy- 12 weeks	480
Triptorelin	Genitourinary	Triptorelin 22.6mg Therapy- 24 weeks	488
		Triptorelin 3mg Therapy- 28 day	489
		Vandetanib Monotherapy	242
Vandetanib	Head & Neck		
Vemurafenib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373
		Vemurafenib Monotherapy	102
Venetoclax	Leukaemia/BMT	Venetoclax Monotherapy	400
Venetoxlax	Leukaemia/BMT	Venetoclax and Rituximab therapy	575
Vinblastine	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days	338
	Sarcoma	VinBLASStine and Methotrexate Therapy	554
	Lymphoma	ABVD Therapy	290
VinCRISStine	Gynaecology	EMA/CO Therapy	248
	Sarcoma	Etoposide and ifosfamide - vinCRISStine, DOXOrubicin and cyclopho:	675
			747
	Neuro-oncology	Procarbazine Lomustine and VinCRISStine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISStine (PCV) Therapy – 56 days	658
		CISplatin, Lomustine and vinCRISStine (CLV) Therapy	806
Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISStine and Prednisolone (*R)-CHOP Therapy– 14 days	409	

VinCRISTine	Lymphoma	(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone	
		(*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		Obinutuzumab and CHOP Therapy – 21 day	549
		obinutuzumab and CVP therapy -21 days	550
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CI	841
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) –	664
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and I	667
Dose Adjusted R (S/C)-EPOCH Therapy	672		
(*riTUXimab)-Gemcitabine Cyclophosphamide VinCRISTine and Pred	737		
Vinorelbine	Breast	Pertuzumab Trastuzumab (Phesgo®) and vinORELbine	798
	Lung	CARBOplatin and vinORELbine Therapy-21 Day	614
Vinorelbine IV	Breast	Intravenous Vinorelbine Monotherapy-21day	232
		Pertuzumab Trastuzumab and VinORELBine	526
	Gynaecology	Intravenous Vinorelbine Monotherapy-21day	232
	Lung	Intravenous Vinorelbine Monotherapy-21day	232
		Vinorelbine and CISplatin Therapy-21 days	339
Vinorelbine and CISplatin Therapy-28 days	343		
Vinorelbine Oral	Breast	Oral Vinorelbine Monotherapy-7days	259
	Lung	Oral Vinorelbine Monotherapy-7days	259
Vismodegib	Skin/Melanoma	Vismodegib Monotherapy	236
Vyxeos liposomal®	Leukaemia/BMT	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction Thera	613
		Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation T	618
Zanubrutinib	Lymphoma	Zanubrutinib Therapy	708
Zoledronic acid	Breast	Zoledronic acid monotherapy	545
	Breast, Genitourin	Zoledronic Acid Therapy-28 days	723
		Zoledronic Acid Therapy-3 monthly	724
		Zoledronic Acid Therapy-6 monthly	725